Small-molecule targeting AMPA-mediated excitotoxicity has therapeutic effects in mouse models for multiple sclerosis

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Current multiple sclerosis (MS) treatments primarily target autoimmune responses causing demyelination.
• Neurodegeneration may precede autoimmune reactions in MS, suggesting alternative therapeutic targets.
• Glutamate excitotoxicity is implicated in MS pathology, but broad glutamate receptor antagonism has functional limitations.

Purpose of the Study:

• To discover a small molecule that selectively prevents AMPA-mediated excitotoxicity.
• To evaluate the therapeutic potential of a novel AMPA receptor modulator in MS models.
• To assess the efficacy and safety profile of the candidate compound, particularly regarding neurotransmission.

Main Methods:

• Machine learning was employed to screen for small molecules targeting the AMPA receptor GluA2 subunit.
• The lead candidate was tested in experimental autoimmune encephalitis (EAE) and cuprizone-induced mouse models of MS.
• Neurological function, myelination, immune response, basal neurotransmission, and learning/memory were assessed.

Main Results:

• A novel small molecule was identified that selectively targets an allosteric site on the AMPA receptor.
• The compound demonstrated potent restoration of neurological function and myelination in MS mouse models.
• Significant reduction in immune response was observed, alongside preservation of basal neurotransmission and cognitive functions.

Conclusions:

• This study presents a promising therapeutic candidate for MS with a novel mechanism of action targeting excitotoxicity.
• The developed small molecule avoids the off-target effects associated with general glutamate receptor antagonists.
• This approach offers a potential alternative or complementary therapy to existing immunomodulatory drugs for multiple sclerosis.